Stockreport

Sunovion Announces Results from Its Open-Label Extension Study of SEP-363856 in Schizophrenia

SUMITOMO CHEM UNSP/ADR  (SOMMY) 
NASDAQ:AMEX Investor Relations: sumitomo-chem.co.jp/english/ir
PDF — SEP-363856 was generally safe and well tolerated throughout the six-month study —— Treatment with SEP-363856 was associated with clinically meaningful improvement acro [Read more]